ISRCTN10853487已完成4 期
A Calcium channel or Angiotensin converting enzyme inhibitor/Angiotensin receptor blocker Regimen to reduce Blood pressure variability in acute ischaemic Stroke (CAARBS): A Feasibility Trial
niversity of Leicester0 个研究点目标入组 14 人开始时间: 2017年10月24日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 14
研究概览
简要总结
2019 protocol in https://www.ncbi.nlm.nih.gov/pubmed/30782930 (added 11/03/2020) 2020 results in https://www.ncbi.nlm.nih.gov/pubmed/32151851 (added 11/03/2020)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Participant inclusion criteria as of 24/09/2018:
- •1. Adult patients (male and female) aged over 18
- •2. First episode TIA or mild to moderate ischaemic stroke (NIHSS <10)
- •3. Blood pressure >130/80mmHg
- •4. Within 7 days of symptom onset
- •5. Willing to comply with randomly assigned blood pressure treatment and blood pressure measurements
- •6. Able to understand verbal and written English
- •7. Able to provide informed consent
- •8. Willing for their GP to be notified of their involvement in the study
- •Previous participant inclusion criteria:
- •1. Adult patients (male and female) aged over 18
- •2. First episode TIA or mild to moderate ischaemic stroke (NIHSS <10)
- •3. Blood pressure >130/80mmHg
- •4. Within 72 hours of symptom onset
- •5. Willing to comply with randomly assigned blood pressure treatment and blood pressure measurements
- •6. Able to understand verbal and written English
- •7. Able to provide informed consent
- •8. Willing for their GP to be notified of their involvement in the study
排除标准
- •1. Known definite contra-indication to BP-lowering regime or therapeutic agents
- •2. Swallowing difficulties which would preclude the taking of oral medication
- •3. Definite indication for beta blocker, calcium channel blocker, angiotensin converting enzyme inhibitor, or angiotensin receptor blocker therapy
- •4. Significant pre-stroke dependency (modified Rankin Score >3)
- •5. Co-existing life-threatening condition with life expectancy <3 months
- •6. Previous participation in this trial or current participation in another investigational drug trial
- •7. Atrial fibrillation
- •8. Female participants who are pregnant, lactating or planning pregnancy during the course of the study
- •9. Participants who intend to donate blood during the study
- •10. Unable to understand verbal and written English
- •11. Cannot give informed consent
研究者
相似试验
进行中（未招募）
1 期
Do two different types of blood pressure lowering therapy (Calcium Channel Blockers or Angiotensin Converting Enzyme Inhibitor/Angiotensin receptor blockers) have similar effects on reducing Blood pressure levels and variability following acute ischaemic Stroke or TIA (CAARBS): A Feasibility TrialEUCTR2017-002560-41-GBniversity of Leicester14
已完成
不适用
The Oxford study of calcium channel antagonism, cognition, mood instability and sleepMood instability, which is a feature of bipolar disorder and other psychiatric disorders including borderline personality disorder, but can also occur in the absence of any diagnosisMental and Behavioural DisordersISRCTN33631053niversity of Oxford32
招募中
不适用
Angiotensin Converting Enzyme rs (1799752) Gene Polymorphism and Development of In-Stent Restenosis in Patients With Stable Coronary Artery Diseases in Sohag Hospital University.Angiotensin Converting Enzyme rs (1799752) Gene Polymorphism and Development of In-Stent Restenosis in Patients With Stable Coronary Artery DiseasesNCT06055673Sohag University182
已完成
1 期
Approved calcium channel blocker in the treatment of fibrodysplasia ossificans progressiva (FOP)fibrodysplasia ossificans progressivaJPRN-UMIN000019348agoya University Graduate School of Medicine5
已完成
不适用
Angiotensin Converting Enzyme (ACE) inhibitors in renal transplant recipients with left ventricular hypertrophyISRCTN94487168Azienda Ospedaliera Universitaria S.Martino (Italy)70